DILIsym Services, Inc. has developed DILIsym® and NAFLDsym® QSP software, and is developing IPFsym™ and RENAsym™ QSP software, to provide the pharmaceutical industry with the tools and resources to efficiently develop safe and effective drug therapies.
DILIsym and RENAsym are designed to address drug-induced liver injury (DILI) and drug-induced acute kidney injury, respectively. NAFLDsym and IPFsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH) and idiopathic pulmonary fibrosis (IPF), respectively. Thus, DILIsym and RENAsym may be applied to address drug safety across therapeutic areas, while NAFLDsym and IPFsym may be applied to support the development of efficacious drugs in these therapeutic areas. DILIsym Services, Inc. makes these tools available to small, mid-size and large pharmaceutical organizations and regulatory agencies through its licensing programs. In addition to performing consulting services using the modeling softwares, the expert scientific team engages clients from initial program design through data input and "results" interpretation.
Our mission is to apply our modeling and simulation expertise to support the development of safe and efficacious drug therapies. We aim to make drug development more efficient for the pharmaceutical industry by informing critical decisions, which will, in turn, lead to an increased availability of vital medicines for the patients who need them. We also promote the advancement of drug safety sciences by making DILIsym software available to academic researchers at accredited academic institutions, and through the Simulations Plus Distinguished Site for M&S Advancement program.
Company Details
- Employees
- 7
- Founded
- -
- Address
- Six Davis Drive,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Software, Consulting Services, Drug-Induced Liver Injury, Modeling & Simulation, Non-alchoholic Fatty Liver Disease, Metabolic Diseases, Non-alcoholic Steatohepatitis, NAFLD, NASH, Biotechnology, Pharmaceuticals, Mathematical Modeling, Quantitative systems pharmacology, Quantitative systems toxicology, Drug-Induced Kidney Injury, Consortium, Acute Kidney Injury, Idiopathic pulmonary fibrosis, Simulated Populations Sim-Pops™, mitochondrial dysfunction, hepatocytes.
- HQ
- Research Triangle Park, North Carolina
Dilisym Services, A Division Of Simulations Plus Questions
Dilisym Services, A Division Of Simulations Plus's website is https://www.simulations-plus.com/dilisym-services/
Dilisym Services, A Division Of Simulations Plus's LinkedIn profile is https://www.linkedin.com/company/dilisym
Dilisym Services, A Division Of Simulations Plus has
7 employees.
View email and phone details for 7
employees at Dilisym Services, A Division Of Simulations Plus.
Dilisym Services, A Division Of Simulations Plus's industry is
Biotechnology Research
Dilisym Services, A Division Of Simulations Plus's top competitors are
Nuventra Pharma Sciences,
Prologue Medicines,
Twenty-Nine Palms Band Of Mission Indians,
Forward Therapeutics, Inc.,
田辺三菱製薬（株）,
Chumash Enterprises,
Applied Biomath,
Simulations Plus, Inc.,
Tizona Therapeutics, Inc.,
Trishula Therapeutics, Inc..
Dilisym Services, A Division Of Simulations Plus's categories are Biotechnology Research
Dilisym Services, A Division Of Simulations Plus's founding year is 2014
